Last edition
News about "EGFR-targeted therapy"
Sandoz and Henlius Partner on up to 10 Biosimilars
Sandoz partners with Henlius on up to 10 biosimilars, expanding its pipeline to 39 assets with potential to reach 46, including cetuximab, evolocumab and belimumab.
EGFR-targeted Therapy | 19/08/2026 | By News Bureau
Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer
Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.
EGFR-targeted Therapy | 01/08/2026 | By News Bureau | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy